Efficacy of olanzapine in adolescents with schizophrenia: Results from a double-blind, placebo-controlled study

被引：0
|
作者：
Kryzhanovskaya, L.
Dittmann, R. W.
Robertson-Plouch, C.
Bauer, T.
Xu, W.
Wang, W. V.
Carlson, J.
Tohen, M.
机构：
[1] Lilly Res Labs, Indianapolis, IN USA
[2] Univ Hamburg, Dept C&A Psychosomat Med, Hamburg, Germany
[3] Harvard Univ, McLean Hosp, Sch Med, Belmont, MA 02178 USA
来源：
INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY | 2006年 / 9卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S276 / S276
页数：1
相关论文
共 50 条
  • [21] Lurasidone for maintenance of efficacy in patients with schizophrenia: a double-blind, placebo-controlled, randomised withdrawal study
    Tandon, R.
    Loebel, A.
    Phillips, D.
    Pikalov, A.
    Hernandez, D.
    Mao, Y.
    Cucchiaro, J.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2014, 24 : S559 - S560
  • [22] Nilvadipine is effective for chronic schizophrenia in a double-blind placebo-controlled study
    Yamada, K
    Kanba, S
    Ashikari, I
    Ohnishi, K
    Yagi, G
    Asai, M
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1996, 16 (06) : 437 - 439
  • [23] Cyproheptadine in treatment of chronic schizophrenia: a double-blind, placebo-controlled study
    Akhondzadeh, S
    Mohammadi, MR
    Amini-Nooshabadi, H
    Davari-Ashtiani, R
    JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, 1999, 24 (01) : 49 - 52
  • [24] A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY OF LURASIDONE FOR THE MAINTENANCE OF EFFICACY IN PATIENTS WITH SCHIZOPHRENIA
    Tandon, R.
    Loebel, A.
    Phillips, D.
    Pikalov, A.
    Hernandez, D.
    Mao, Y.
    Cucchiaro, J.
    EUROPEAN PSYCHIATRY, 2014, 29
  • [25] A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED WITHDRAWAL STUDY OF LURASIDONE FOR THE MAINTENANCE OF EFFICACY IN PATIENTS WITH SCHIZOPHRENIA
    Tandon, Rajiv
    Loebel, Antony
    Phillips, Debra
    Pikalov, Andrei
    Hernandez, David
    Mao, Yongcai
    Cucchiaro, Josephine
    SCHIZOPHRENIA RESEARCH, 2014, 153 : S372 - S372
  • [26] A double-blind, placebo-controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia
    Tandon, Rajiv
    Cucchiaro, Josephine
    Phillips, Debra
    Hernandez, David
    Mao, Yongcai
    Pikalov, Andrei
    Loebel, Antony
    JOURNAL OF PSYCHOPHARMACOLOGY, 2016, 30 (01) : 69 - 77
  • [27] EFFICACY OF LOW DOSE LURASIDONE IN PATIENTS WITH SCHIZOPHRENIA: RESULTS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL
    Kane, John M.
    Silva, Robert
    Goldman, Robert
    Watabe, Kei
    Cucchiaro, Josephine
    Loebel, Antony
    SCHIZOPHRENIA BULLETIN, 2015, 41 : S317 - S317
  • [28] Attenuation of olanzapine-induced weight gain with reboxetine in patients with schizophrenia: A double-blind, placebo-controlled study
    Poyurovsky, M
    Isaacs, I
    Fuchs, C
    Schneidman, M
    Faragian, S
    Weizman, R
    Weizman, A
    AMERICAN JOURNAL OF PSYCHIATRY, 2003, 160 (02): : 297 - 302
  • [29] Venlafaxine for panic disorder: Results from a double-blind, placebo-controlled study
    Pollack, MH
    Worthington, JJ
    Otto, MW
    Maki, KM
    Smoller, JW
    Manfro, GG
    Rudolph, R
    Rosenbaum, JF
    PSYCHOPHARMACOLOGY BULLETIN, 1996, 32 (04) : 667 - 670
  • [30] Efficacy and tolerability of almotriptan in adolescents: A randomized, double-blind, placebo-controlled trial
    Linder, Steven L.
    Mathew, Ninan T.
    Cady, Roger K.
    Finlayson, Gary
    Ishkanian, Gary
    Lewis, Donald W.
    HEADACHE, 2008, 48 (09): : 1326 - 1336
12345